Biotech Values

[DewDiligence]

TLCV spin-off for AMD treatment increases IPO price range:

[Be careful with this one --I’m not convinced that rheopheresis isn’t a hoax. Please see #msg-3054537 and #msg-2404229 for background info.]

http://tinyurl.com/5yd4n

>>
OccuLogix increases IPO price to $10-$12 per share

WASHINGTON, Dec 6 (Reuters) - Eye disease treatment company OccuLogix Inc. filed on Monday to increase the price of its planned initial public offering to $10 to $12 per share from $8 to $10 a share.

The company still plans to sell 5.6 million shares in the offering, and shareholders intend to sell an additional 2.8 million shares, according to an amended prospectus filed with the U.S. Securities and Exchange Commission.

OccuLogix has been approved to list its common stock on the Nasdaq under the symbol "RHEO" (RHEO.O: Quote, Profile, Research) .
<<